Phenotypes Associated with This Genotype

Genotype
MGI:6273496

• Allelic Composition: Runx1^tm3Spe/Runx1^tm3Spe; U2af1^tm1.1Hev/U2af1⁺; Tg(Mx1-cre)1Cgn/0
• Genetic Background: involves: 129S4/SvJae * 129S6/SvEvTac * BALB/c * C57BL/6 * CBA/J

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

hematopoietic system

abnormal blood cell morphology ( J:267082 )

• poly (IC) treated mice develop multilineage cytopenia

abnormal myeloid cell morphology ( J:267082 )

• mice develop low-level myeloid dysplasia after poly (IC) treatment

thrombocytopenia ( J:267082 )

• mice develop thrombocytopenia after poly (IC) treatment

increased myeloid cell number ( J:267082 )

• mice exhibit an increased percentage of myeloid cells and increased myeloid colony formation after poly (IC) treatment

abnormal erythroid lineage cell morphology ( J:267082 )

• mice develop low-level erythroid dysplasia after poly (IC) treatment

homeostasis/metabolism

increased incidence of tumors by chemical induction ( J:267082 )

• one mouse treated with ENU after poly (IC) treatment developed acute myeloid leukemia

• mice treated with ENU after poly (IC) treatment exhibit increased percentages of myeloid cells in the peripheral blood, enlarged spleen, and extramedullary hematopoiesis, occasional low-grade dysplasia in the erythroid and neutrophil lineages indicating the development of myeloproliferative neoplasm

mortality/aging

mortality/aging ( J:267082 )

N • poly (IC) treated mice have a normal life span and do not develop frank leukemia within 1.5 years after poly (IC) treatment

increased susceptibility to induced morbidity/mortality ( J:267082 )

• mice treated with ENU after poly (IC) treatment die prematurely with myeloid pathology

neoplasm

increased incidence of tumors by chemical induction ( J:267082 )

• one mouse treated with ENU after poly (IC) treatment developed acute myeloid leukemia

• mice treated with ENU after poly (IC) treatment exhibit increased percentages of myeloid cells in the peripheral blood, enlarged spleen, and extramedullary hematopoiesis, occasional low-grade dysplasia in the erythroid and neutrophil lineages indicating the development of myeloproliferative neoplasm